The Korean journal of internal medicine

The Korean Association of Internal Medicine (대한내과학회)
권호 표지
DOI QR코드

DOI QR Code

Third-party regulatory T cells prevent murine acute graft-versus-host disease

  • Lim, Jung-Yeon (Institute for Translational Research and Molecular Imaging, College of Medicine, The Catholic University of Korea) ;
  • Im, Keon-Il (Institute for Translational Research and Molecular Imaging, College of Medicine, The Catholic University of Korea) ;
  • Song, Yunejin (Institute for Translational Research and Molecular Imaging, College of Medicine, The Catholic University of Korea) ;
  • Kim, Nayoun (Institute for Translational Research and Molecular Imaging, College of Medicine, The Catholic University of Korea) ;
  • Nam, Young-Sun (Institute for Translational Research and Molecular Imaging, College of Medicine, The Catholic University of Korea) ;
  • Jeon, Young-Woo (Institute for Translational Research and Molecular Imaging, College of Medicine, The Catholic University of Korea) ;
  • Cho, Seok-Goo (Institute for Translational Research and Molecular Imaging, College of Medicine, The Catholic University of Korea)
  • Received : 2016.10.05
  • Accepted : 2016.12.30
  • Published : 2018.09.01
⟨ Previous Next ⟩

Abstract

Background/Aims: Adoptive therapy with regulatory T (Treg) cells to prevent graft-versus-host disease (GVHD) would benefit from a strategy to improve homing to the sites of inf lammation following hematopoietic stem cell transplantation (HSCT). Although donor-derived Treg cells have mainly been used in these models, third-party-derived Treg cells are a promising alternative for cell-based immunotherapy, as they can be screened for pathogens and cell activity, and banked for GVHD prevention. In this study, we explored major histocompatibility complex (MHC) disparities between Treg cells and conventional T cells in HSCT to evaluate the impact of these different cell populations on the prevention of acute GVHD, as well as survival after allogeneic transplantation. Methods: To induce acute GVHD, lethally irradiated BALB/c (H-2d) mice were transplanted with $5{\times}10^5$ T cell-depleted bone marrow cells and $5{\times}10^5$ CD4+CD25-splenic T cells from C57BL/6 (H-2b) mice. Recipients were injected with $5{\times}10^5$ cultured donor-, host-, or third-party-derived CD4+CD25+CD62L+ Treg cells (bone marrow transplantation + day 1). Results: Systemic infusion of three groups of Treg cell improved clinicopathological manifestations and survival in an acute GVHD model. Although donor-derived Treg cells were immunologically the most effective, the third-party-derived Treg cell therapy group displayed equal regulation of expansion of CD4+CD25+Foxp3+Treg cells and suppressive CD4+IL-17+ T-helper (Th17) cells in ex vivo assays compared with the donor- and host-derived groups. Conclusions: Our findings demonstrate that the use of third-party Treg cells is a viable alternative to donor-derived Treg cellular therapy in clinical settings, in which human leukocyte antigen-matched donors are not always readily available.

Keywords

Acknowledgement

Supported by : Seoul St. Mary's Hospital, The Catholic University of Korea, National Research Foundation of Korea

References

  1. Cao J, Chen C, Zeng LY, et al. Influence of donor Treg cells on GVHD and GVL effects after allogeneic bone marrow transplantation in mice. Zhongguo Shi Yan Xue Ye Xue Za Zhi 2010;18:181-184.
  2. Kataoka Y, Iwasaki T, Kuroiwa T, et al. The role of donor T cells for target organ injuries in acute and chronic graftversus-host disease. Immunology 2001;103:310-318. https://doi.org/10.1046/j.1365-2567.2001.01240.x
  3. Gallatin WM, Weissman IL, Butcher EC. A cell-surface molecule involved in organ-specific homing of lymphocytes. Nature 1983;304:30-34. https://doi.org/10.1038/304030a0
  4. Fu S, Yopp AC, Mao X, et al. CD4+ CD25+ CD62+ T-regulatory cell subset has optimal suppressive and proliferative potential. Am J Transplant 2004;4:65-78. https://doi.org/10.1046/j.1600-6143.2003.00293.x
  5. Brunstein CG, Miller JS, Cao Q, et al. Infusion of ex vivo expanded T regulatory cells in adults transplanted with umbilical cord blood: safety profile and detection kinetics. Blood 2011;117:1061-1070. https://doi.org/10.1182/blood-2010-07-293795
  6. Jeon EJ, Yoon BY, Lim JY, et al. Adoptive transfer of all-trans-retinal-induced regulatory T cells ameliorates experimental autoimmune arthritis in an interferon-gamma knockout model. Autoimmunity 2012;45:460-469. https://doi.org/10.3109/08916934.2012.682666
  7. Fukui J, Inaba M, Ueda Y, et al. Prevention of graft-versushost disease by intra-bone marrow injection of donor T cells. Stem Cells 2007;25:1595-1601. https://doi.org/10.1634/stemcells.2006-0234
  8. Lee ES, Lim JY, Im KI, et al. adoptive transfer of treg cells combined with mesenchymal stem cells facilitates repopulation of endogenous Treg cells in a murine acute GVHD model. PLoS One 2015;10:e0138846. https://doi.org/10.1371/journal.pone.0138846
  9. Lim JY, Park MJ, Im KI, et al. Combination cell therapy using mesenchymal stem cells and regulatory T-cells provides a synergistic immunomodulatory effect associated with reciprocal regulation of TH1/TH2 and th17/treg cells in a murine acute graft-versus-host disease model. Cell Transplant 2014;23:703-714. https://doi.org/10.3727/096368913X664577
  10. Shi M, Adachi Y, Cui Y, et al. Combination of intra-bone marrow-bone marrow transplantation and subcutaneous donor splenocyte injection diminishes risk of graft-versus-host disease and enhances survival rate. Stem Cells Dev 2011;20:759-768. https://doi.org/10.1089/scd.2010.0232
  11. Riley JL, June CH, Blazar BR. Human T regulatory cell therapy: take a billion or so and call me in the morning. Immunity 2009;30:656-665. https://doi.org/10.1016/j.immuni.2009.04.006
  12. Fozza C, Dazzi F. Regulatory T cells in stem cell transplantation: main characters or walk-on actors? Crit Rev Oncol Hematol 2012;84:18-25. https://doi.org/10.1016/j.critrevonc.2012.02.003
  13. Rezvani K, Mielke S, Ahmadzadeh M, et al. High donor FOXP3-positive regulatory T-cell (Treg) content is associated with a low risk of GVHD following HLA-matched allogeneic SCT. Blood 2006;108:1291-1297. https://doi.org/10.1182/blood-2006-02-003996
  14. Li Q, Zhai Z, Xu X, et al. Decrease of CD4(+)CD25(+) regulatory T cells and TGF-beta at early immune reconstitution is associated to the onset and severity of graft-versushost disease following allogeneic haematogenesis stem cell transplantation. Leuk Res 2010;34:1158-1168. https://doi.org/10.1016/j.leukres.2010.03.017
  15. Koenecke C, Czeloth N, Bubke A, et al. Alloantigen-specific de novo-induced Foxp3+ Treg revert in vivo and do not protect from experimental GVHD. Eur J Immunol 2009;39:3091-3096. https://doi.org/10.1002/eji.200939432
  16. Beres AJ, Haribhai D, Chadwick AC, Gonyo PJ, Williams CB, Drobyski WR. CD8+ Foxp3+ regulatory T cells are induced during graft-versus-host disease and mitigate disease severity. J Immunol 2012;189:464-474. https://doi.org/10.4049/jimmunol.1200886
  17. Zheng SG, Wang JH, Koss MN, Quismorio F Jr, Gray JD, Horwitz DA. CD4+ and CD8+ regulatory T cells generated ex vivo with IL-2 and TGF-beta suppress a stimulatory graft-versus-host disease with a lupus-like syndrome. J Immunol 2004;172:1531-1539. https://doi.org/10.4049/jimmunol.172.3.1531
  18. Yamashita J, Koi K, Yang DY, McCauley LK. Effect of zoledronate on oral wound healing in rats. Clin Cancer Res 2011;17:1405-1414. https://doi.org/10.1158/1078-0432.CCR-10-1614
  19. Lu SY, Liu KY, Liu DH, Xu LP, Huang XJ. High frequencies of CD62L+ naive regulatory T cells in allografts are associated with a low risk of acute graft-versus-host disease following unmanipulated allogeneic haematopoietic stem cell transplantation. Clin Exp Immunol 2011;165:264-277. https://doi.org/10.1111/j.1365-2249.2011.04418.x
  20. Taylor PA, Panoskaltsis-Mortari A, Swedin JM, et al. L-Selectin(hi) but not the L-selectin(lo) CD4+25+ T-regulatory cells are potent inhibitors of GVHD and BM graft rejection. Blood 2004;104:3804-3812. https://doi.org/10.1182/blood-2004-05-1850
  21. Ermann J, Hoffmann P, Edinger M, et al. Only the CD62L+ subpopulation of CD4+CD25+ regulatory T cells protects from lethal acute GVHD. Blood 2005;105:2220-2226. https://doi.org/10.1182/blood-2004-05-2044
  22. Parmar S, Liu X, Tung SS, et al. Third-party umbilical cord blood-derived regulatory T cells prevent xenogenic graft-versus-host disease. Cytotherapy 2014;16:90-100. https://doi.org/10.1016/j.jcyt.2013.07.009

Cited by

  1. Suppressive Characteristics of Umbilical Cord Blood-derived Regulatory T Cells After Ex Vivo Expansion on Autologous and Allogeneic T Effectors and Various Lymphoblastic Cells vol.42, pp.4, 2018, https://doi.org/10.1097/cji.0000000000000262